中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (7): 529-534.doi: 10.3969/j.issn.1007-3969.2015.07.007

• 论著 • 上一篇    下一篇

高危型妊娠滋养细胞肿瘤的评估与治疗

于海林,奚美丽,李俊,鹿欣   

  1. 复旦大学附属妇产科医院妇科,上海 200011
  • 出版日期:2015-07-30 发布日期:2015-12-09
  • 通信作者: 鹿欣 E-mail:xinludoc@163.com

Evaluation and management of high-risk gestational trophoblastic neoplasm

YU Hailin, XI Meili, LI Jun, LU Xin   

  1. Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China
  • Published:2015-07-30 Online:2015-12-09
  • Contact: LU Xin E-mail: xinludoc@163.com

摘要:

背景与目的:妊娠滋养细胞肿瘤(gestational trophoblastic neoplasm,GTN)是一组起源于胎盘滋养细胞的疾病,因为化疗敏感,绝大多数GTN患者的预后良好。然而,对于高危型GTN由于化疗耐药以及肿瘤复发的存在,其治愈率仅为70%~80%。该研究旨在分析复旦大学附属妇产科医院10年间高危型GTN的诊疗情况。方法:收集2003年1月—2013年1月该院高危型GTN患者的临床资料,从化疗、手术等方面分析其临床特点及其临床转归。结果:10年间我院共收治高危型GTN患者51例,其中5例患者因未完成治疗予以排除,故仅对46例高危型GTN患者予以评估。46例高危型GTN患者,单纯化疗27例,化疗联合手术19例。44例高危型GTN患者接受以EMA-CO(依托泊苷+甲氨蝶呤+Act-D/长春新碱+环磷酰胺)化疗方案为基础的治疗,其中36例患者获得完全缓解(completed response,CR),CR率为81.82%(36/44),8例对EMA-CO耐药;8例EMA-CO化疗方案耐药的患者中,6例更换为EMA-EP(依托泊苷+甲氨蝶呤+Act-D/顺铂+依托泊苷)方案(其中2例接受手术治疗)后获得CR,2例因耐药、疾病进展最终死亡。余2例高危型GTN患者采用其他化疗方案(1例5-FU+KSM,另1例因误诊为持续性异位妊娠接受MTX方案化疗,待手术病理证实为绒癌后由MTX更换为EMA-CO方案)获得CR,故46例患者中,CR率为95.65%(44/46)。19例手术患者中,1例因化疗耐药死亡,余18例均经化疗联合手术治疗获得CR,故手术联合化疗者CR率94.70%(18/19)。结论:规范的联合化疗对提高高危型GTN的完全缓解率至关重要,手术治疗在高危型GTN治疗中的作用不可忽视。

关键词: 妊娠滋养细胞肿瘤, 高危型妊娠滋养细胞肿瘤, 联合化疗

Abstract: Background and purpose: Gestational trophoblastic neoplasm (GTN) is a spectrum of disease arising from trophoblastic cells, and the majority of patients with GTN have favorable outcome because of the sensitivity to chemotherapy. While the cure rate for high-risk patients is still 70% to 80% as a result of drug resistance and disease recurrence. This study aimed to evaluate the clinical characteristics and outcome of patients with high-risk GTN. Methods: The clinical records of patients with high-risk GTN treated in Obstetrics and Gynecology Hospital of Fudan University from Jan. 2003 to Jan. 2013 were analyzed and reviewed retrospectively from the aspect of different treatment. Results: Fifty-one patients with high-risk GTN were admitted to this hospital. Among 51 high-risk GTN patients, 46 patients were evaluated retrospectively and 5 patients were excluded for incomplete treatments. Of the 46 patients with high-risk GTN, 27 patients were treated by chemotherapy alone, 19 patients received chemotherapy and adjuvant surgical therapy. Forty-four patients received EMA-CO (VP-16+Act-D+MTX/VCR+CTX) as a first-line chemotherapy, 81.82% (36/44) had complete remission and 8 patients developed resistance to EMA-CO. EMA-EP (VP- 16+Act-D+MTX/VP-16+cisplatin) was used as second-line chemotherapy for the 8 patients resistant to EMA-CO, 6 patients (2 underwent adjuvant surgical therapy) achieved remission and 2 patients died as a result of drug-resistance and disease progression. For the remaining 2 patients, one was treated by 5-FU+KSM and pulmonary resection, and the other was treated by MTX for misdiagnosis as ectopic pregnancy and then converted to EMA-CO for the pathological diagnosis of choriocarcinoma after surgery. Both of them achieved complete remission. Ultimately, 95.65% (44/46) patients achieved complete remission. Among the 19 patients who underwent adjuvant surgical therapy, 94.70% (18/19) patients achieved complete remission after chemotherapy and adjuvant surgery, and the remaining one patient died of disease progression. Conclusion: Standard combination chemotherapy is crucial in the treatment of high-risk GTN. The role of adjuvant surgery in the management of high-risk GTN should not be underestimated.

Key words: Gestational trophoblastic neoplasm, High-risk gestational trophoblastic neoplasm, Combination chemotherapy